Evaxion announces completion of ADS ratio change
- COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company's previously disclosed ratio change of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective.
- 01/14/2025
|
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
- COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the “ADS ratio change”).
- 01/10/2025
|
Evaxion announces plan to implement ADS ratio change
- COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the “ADS ratio change”). The ADS ratio change is expected to become effective on or about January 13, 2025, U.S. Eastern Time (the “effective date”).
- 12/30/2024
|
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
- COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new positive preclinical data from its ongoing cytomegalovirus (CMV) vaccine program named EVX-V1. The data will be presented today at the 9th International Conference on Vaccines Research & Development, taking place in Boston, USA.
- 11/12/2024
|
Evaxion announces business update and third quarter 2024 financial results
- COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results.
- 10/31/2024
|
Evaxion to announce business update and third quarter 2024 financial results on October 31
- COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.
- 10/28/2024
|
Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
- COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence from three different clinical trials validating the vaccine target predictions of its AI platform.
- 10/09/2024
|
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
- COPENHAGEN, Denmark, October 3, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, continues to gather clinical evidence for the steady improvement of its AI-Immunology™ platform.
- 10/03/2024
|
Evaxion significantly expands vaccine development collaboration with MSD
- COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it has entered into an option and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) for two preclinical vaccine candidates. The agreement expands the companies' current collaboration and carries significant value for Evaxion.
- 09/26/2024
|
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
- COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, launches an enhanced version of its clinically validated AI-Immunology™ platform with an update of its EDEN™ AI prediction model. Among other improvements, the model can now predict toxin antigens, allowing for the development of improved bacterial vaccines.
- 09/19/2024
|
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
- COPENHAGEN, Denmark, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new pre-clinical data demonstrating the ability of its novel EVX-B2 mRNA Gonorrhea vaccine candidate in eliminating gonorrhea bacteria by triggering a targeted immune response.
- 09/09/2024
|
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript
- Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Mads Kronborg - Vice President, Investor Relations & Communication Conference Call Participants Li Chen - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Chong Liu - Ladenburg Operator Good day and thank you for standing by.
- 08/14/2024
|
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
- COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM.
- 08/12/2024
|
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
- COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is proud to announce the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024. The EVX-01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma (skin cancer).
- 08/08/2024
|
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
- COPENHAGEN, Denmark, July 16, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today showcases improved performance of its key building block, EvaxMHC, within its AI-Immunology™ platform, at the 32nd Intelligent Systems for Molecular Biology (ISMB) conference taking place in Montreal, Canada, from July 12-16, 2024.
- 07/16/2024
|
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
- COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.
- 07/03/2024
|
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
- COPENHAGEN, Denmark, June 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives positive feedback on its recent patent application for a new type of personalized vaccine targets, underscoring its novelty and inventiveness.
- 06/26/2024
|
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
- COPENHAGEN, Denmark, June 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces publication of data from its Phase 1 dose escalation study of its lead personalized cancer vaccine candidate, EVX-01, for metastatic melanoma. The study results, published in the Journal for ImmunoTherapy of Cancer , demonstrated that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses. Further, EVX-01 immunization did not induce vaccine-related serious adverse events in patients co-administered with anti-PD1 therapy.
- 06/17/2024
|
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
- Evaxion Biotecch (EVAX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 06/13/2024
|
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
- COPENHAGEN, Denmark, June 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, reported data from its ongoing Phase 2 study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The data demonstrated vaccine-induced immune response in metastatic melanoma patients treated with the Company's AI-Immunology™ designed personalized cancer vaccine, EVX-01, in combination with an anti-PD1 inhibitor. The EVX-01 vaccine targets neoantigens - antigenic sequences derived from cancer mutations - that are displayed on the surface of the cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells.
- 06/03/2024
|
Evaxion Announces Business Update and First Quarter 2024 Financial Results
- COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results.
- 05/28/2024
|
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
- COPENHAGEN, Denmark, May 23, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study. The study assesses the personalized cancer vaccine EVX-01 in combination with anti-PD1 therapy in patients with advanced melanoma. The conference will take place in Chicago, IL, from May 31 – June 4, 2024.
- 05/23/2024
|
Evaxion Receives Nasdaq Notification
- COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement.
- 05/10/2024
|
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
- COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).
- 04/17/2024
|
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
- Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
- 04/03/2024
|
Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript
- Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Richard Ramanius - Redeye Christian Kanstrup Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results.
- 04/02/2024
|
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
- COPENHAGEN, Denmark, April 02, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion's preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus). In the animal studies, the EVX-B1 antigens significantly reduced disease burden. Currently, the two companies are engaged in discussions regarding the path forward.
- 04/02/2024
|
EVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023
- Evaxion Biotech (NASDAQ: EVAX ) just reported results for the fourth quarter of 2023. Evaxion Biotech reported earnings per share of -$1.60.
- 03/27/2024
|
Evaxion Announces Business Update and Full Year 2023 Financial Results
- COPENHAGEN, Denmark, March 27, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
- 03/27/2024
|
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
- COPENHAGEN, Denmark, March 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform. The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here.
- 03/19/2024
|
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
- COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST.
- 02/29/2024
|
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
- COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique capabilities and know-how.
- 02/20/2024
|
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
- COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).
- 02/07/2024
|
Evaxion Announces Closing of $15 Million Public Offering
- COPENHAGEN, Denmark, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing on February 5, 2024 of its previously announced public offering of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) and accompanying warrant. MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering. The warrants have an exercise price of $4.00 per ADS, are exercisable immediately upon issuance and will expire five years following the date of issuance. Each ADS represents ten ordinary shares of the Company.
- 02/06/2024
|
Evaxion Biotech Announces Pricing of $15 Million Public Offering
- COPENHAGEN, Denmark, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) and accompanying warrant. MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, is also participating in this offering. The warrants will have an exercise price of $4.00 per ADS, will be exercisable immediately upon issuance and will expire five years following the date of issuance. Each ADS represents ten ordinary shares of the Company. The closing of the offering is expected to occur on or about February 5, 2024, subject to the satisfaction of customary closing conditions.
- 02/01/2024
|
This AI-enabled biotech stock nearly doubled on Wednesday: here's why
- Evaxion Biotech (NASDAQ: EVAX) opened nearly 100% up on Wednesday after announcing an “expanded commitment” to developing novel cancer vaccines. Evaxion Biotech stock is rallying today The tailored vaccines will tap on artificial intelligence to identify tumour antigens known broadly as Endogenous Retroviruses (ERVs).
- 01/24/2024
|
Why Is Evaxion Biotech (EVAX) Stock Up 30% Today?
- Evaxion Biotech (NASDAQ: EVAX ) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE: MRK ). A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion Biotech.
- 01/24/2024
|
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
- COPENHAGEN, Denmark, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).
- 01/24/2024
|
Evaxion Announces Completion of ADS Ratio Change
- COPENHAGEN, Denmark, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company's previously disclosed change to its ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective. The ratio has changed from one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change became effective on January 22, 2024 (the “Effective Date”).
- 01/22/2024
|
Evaxion Announces Plan to Implement ADS Ratio Change
- COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), from the current one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change is expected to become effective on or about January 22, 2024, U.S. Eastern Time (the “Effective Date”).
- 01/08/2024
|
Evaxion Biotech Announces Closing of Private Placement
- COPENHAGEN, Denmark, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of its previously announced private placement (the “Private Placement”) with a gross proceed of $5.3 million. The Private Placement included participation from existing and new shareholders, with the largest new shareholder being MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, accounting for some 25% of the total aggregate offering amount. Further, the Private Placement included significant participation by all members of the Company's management and the Company's board of directors.
- 12/21/2023
|
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
- COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provided a business update and announced its third quarter 2023 financial results.
- 12/19/2023
|
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
- Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
- 09/21/2023
|
Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Call Transcript
- Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by.
- 08/22/2023
|
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
- COPENHAGEN, Denmark, July 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA.
- 07/31/2023
|
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
- COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.
- 03/14/2023
|
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
- COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.
- 12/15/2022
|
Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today
- High volume penny stocks to watch before next week. The post Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/23/2022
|
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
- Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.
- 09/22/2022
|
Good Penny Stocks to Add to Your Buy List? 3 to Watch
- Which penny stocks are on your buy list right now? The post Good Penny Stocks to Add to Your Buy List?
- 09/22/2022
|
Why Is Evaxion Biotech (EVAX) Stock Up Today?
- Today's price action (prior to the Federal Reserve's rate hike decision at least) has been broadly positive. But for investors in Evaxion Biotech (NASDAQ: EVAX ), it's been a heck of a day.
- 09/21/2022
|
Evaxion Biotech A/S (EVAX) CEO Lars Wegner on Q2 2022 Results - Earnings Call Transcript
- Evaxion Biotech A/S (EVAX) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Corey Davis - Managing Director, Investor Relations, LifeSci Advisors Lars Wegner - President and CEO Bo Karmark - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good morning, and welcome to the Evaxion Biotech Second Quarter 2022 Earnings Call. All participants will be in a listen-only mode.
- 08/10/2022
|
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10
- COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its second-quarter 2022 financial results on August 10 at 8.30 a.m. EDT.
- 07/29/2022
|
Evaxion Biotech A/S' (EVAX) CEO Lars Wegner on Q1 2022 Results - Earnings Call Transcript
- Evaxion Biotech A/S (EVAX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Corey Davis – LifeSci Advisors Lars Wegner – Chief Executive Officer Jesper Nyegaard Nissen – Interim Chief Financial Officer Conference Call Participants Kevin DeGeeter – Oppenheimer Ahu Demir – Ladenburg Thomas Flaten – Lake Street Operator Greetings, and welcome to the Evaxion Biotech First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
- 05/11/2022
|
Good Penny Stocks To Buy Now? 4 For Your May Watch List
- Penny stocks to watch this week. The post Good Penny Stocks To Buy Now?
- 05/10/2022
|
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11
- COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its first-quarter 2022 financial results on May 11 at 8.30 a.m. EDT.
- 04/29/2022
|
Evaxion Biotech (EVAX) Stock: Why The Price Surged Today
- The stock price of Evaxion Biotech (NASDAQ: EVAX) increased by over 284% during intraday trading today. This is why it happened.
- 11/04/2021
|
Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award
- COPENHAGEN, Denmark, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has been awarded this year's Enabling Technology Leadership Award in the artificial intelligence-enabled drug discovery industry by global research and consulting firm Frost & Sullivan. The award recognizes Evaxion's pioneering spirit towards cutting-edge technology and data-driven decision-making.
- 10/14/2021
|
Evaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021
- COPENHAGEN, Denmark, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today a presentation by Emma Christine Jappe, PhD, Senior Scientist, Research & Development, at the Immuno UK conference being held in London on October 13-14, 2021.
- 10/12/2021
|
Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer
- COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately.
- 09/21/2021
|
Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update
- COPENHAGEN, Denmark, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the second quarter 2021 financial results and provided an operational update.
- 08/12/2021
|
Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02
- COPENHAGEN, Denmark, July 08, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today results from both its Phase 1/2a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 1/2a trial of cancer immunotherapy EVX-02 in adjuvant melanoma.
- 07/08/2021
|
Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8
- COPENHAGEN, Denmark, July 07, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will hold a conference call to discuss Phase 1/2a data on EVX-01 and EVX-02 on Thursday, July 8, 2021.
- 07/07/2021
|
Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming
- COPENHAGEN, Denmark, June 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the acceptance of a new scientific paper by the International Conference on Machine Learning ( ICML 2021 ). A draft of the article is available on the open-access scientific server bioRxiv.org .
- 06/25/2021
|
Evaxion Biotech A/S (EVAX) CEO Lars Wegner on Q1 2021 Results - Earnings Call Transcript
- Evaxion Biotech A/S (EVAX) CEO Lars Wegner on Q1 2021 Results - Earnings Call Transcript
- 05/14/2021
|
Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update
- COPENHAGEN, Denmark, May 13, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the first quarter 2021 financial results and provided an operational update.
- 05/13/2021
|
Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy
- COPENHAGEN, Denmark, April 20, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today a presentation by Jens Kringelum, PhD, Evaxion's Director in Genomic Immuno-Oncology, at the 4th Neoantigen Summit Europe, being held virtually April 20-22, focusing on “AI in personalized cancer medicine”. The presentation described Evaxion's recent improvement in determining cancer neoepitopes through measurement and prediction of peptide-MHC (pMHC) complex stability.
- 04/20/2021
|
Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update
- COPENHAGEN, Denmark, April 06, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the fourth quarter and full year 2020 financial results and provided an operational update.
- 04/06/2021
|
Evaxion Biotech to Host Full-Year 2020 Corporate Update Conference Call & Webcast on April 6
- COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it will present its full-year financial results for 2020 on April 6.
- 03/30/2021
|
Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports
- COPENHAGEN, Denmark, March 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper in the peer-reviewed journal Scientific Reports, describing a study into the bacterium Staphylococcus aureus (S. aureus). The paper can be accessed here: www.nature.com/articles/s41598-021-84050-x
- 03/16/2021
|
Evaxion Biotech Opens New Office and Laboratories to Support Future Growth
- COPENHAGEN, Denmark, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the opening of its new corporate headquarters and research laboratory facility located in the DTU Science Park in Hoersholm near Copenhagen, Denmark.
- 02/16/2021
|
